Ignite Creation Date:
2024-05-05 @ 11:20 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00002097
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-11-02
Brief Title:
A Phase III Clinical Study of Nystatin IV Intravenous in Patients With HIV Infection
Sponsor:
Argus Pharmaceuticals
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
A Phase III Clinical Study of Nystatin IV Intravenous in Patients With HIV Infection
Status:
COMPLETED
Status Verified Date:
1994-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the clinical toxicity safety and maximum tolerated dose MTD of intravenous nystatin in patients with HIV infection To evaluate the potential anti-HIV activity and clinical pharmacology of intravenous nystatin
Detailed Description:
Cohorts of three patients each are treated at escalating doses of intravenous nystatin administered every other day until the MTD is reached Each cohort is observed for toxicity for at least 2 weeks before escalation in subsequent patient cohorts is initiated
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| AR-91-35606-004 | None | None | None |